MARKET

NVRO

NVRO

Nevro
NYSE

Real-time Quotes | Nasdaq Last Sale

140.41
+3.12
+2.27%
Opening 12:15 08/06 EDT
OPEN
137.48
PREV CLOSE
137.29
HIGH
145.29
LOW
135.39
VOLUME
306.36K
TURNOVER
--
52 WEEK HIGH
148.05
52 WEEK LOW
60.85
MARKET CAP
4.77B
P/E (TTM)
-51.7736
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVRO stock price target is 139.56 with a high estimate of 170.00 and a low estimate of 116.00.

EPS

NVRO News

More
Nevro EPS beats by $0.43, beats on revenue
Nevro (NYSE:NVRO): Q2 GAAP EPS of -$1.21 beats by $0.43. Revenue of $56.39M (-39.7% Y/Y) beats by $18.53M. Press Release
seekingalpha · 14h ago
Nevro (NVRO) Reports Q2 Loss, Tops Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of 26.67% and 36.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 18h ago
Nevro Option Alert: Aug 21 $140 Calls at the Ask: 400 @ $5.8 vs 2149 OI; Earnings 8/5 After Close Ref=$135.3
Benzinga · 2d ago
Why Nevro Corp (NVRO) Stock is a Compelling Investment Case
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Small-Cap Growth Fund posted a return of 34.59% for the quarter, outperforming its benchmark, the Russell 2000 Growth Index which returned 30.59% in the sa
Insider Monkey · 6d ago
Nevro (NVRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 16:33
­Nevro to Report Second Quarter 2020 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 a
PR Newswire · 07/20 11:00
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
Investor confidence is high on Nevro (NVRO), thanks to solid prospects
Zacks · 07/10 12:46
Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to $145
Morgan Stanley maintains Nevro (NYSE:NVRO) with a Overweight and raises the price target from $135 to $145.
Benzinga · 06/18 11:51

Industry

Medical Equipment, Supplies & Distribution
-1.77%
Healthcare Equipment & Supplies
-1.77%

Hot Stocks

Symbol
Price
%Change

About NVRO

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.
More

Webull offers kinds of Nevro Corp stock information, including NYSE:NVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVRO stock methods without spending real money on the virtual paper trading platform.